
Product Data Sheet

Product Name: ReN-1869 hydrochloride (NNC-05-1869 hydrochloride)

Cat. No.: GC31812

Chemical Properties

Cas. No. 170149-76-5

SMILES O=C([C@H]1CN(CC/C=C2C3=CC=CC=C3CCC4=CC=CC=C\24)CCC1)O.[H]ClFormula $C_{24}H_{28}ClNO_2$ M.Wt 397.94Solubility Soluble in DMSO Storage Store at $-20^{\circ}C$

General tips For obtaining a higher solubility , please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Kinase experiment:**

ReN 1869 is labelled with 3H in the tricyclic ring system resulting in a specific activity of 40 Ci/mmol. Thawed membranes (1 mg protein/tube), test compounds and [3H]ReN 1869 are added to test tubes in a final volume of 0.5 mL. Unless otherwise indicated, the concentration of the radioligand is 5 nM and non-specific binding is defined as the binding in the presence of 10 μM ReN 1869. Samples are incubated for 120 min at $37^{\circ}C$ in a shaking water bath. Free and bound radioactivity is separated by filtration over Whatman GF/F filters that are washed with 25 mL of ice-cold buffer (20 mM Tris-HCl, pH 7.4). Radioligand bound to filters accounted for 5-700 dpm that is subtracted before calculating specific binding[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

[1]. Olsen UB,
et al. ReN
1869, a novel
tricyclic
antihistamine,
is active
against
neurogenic
pain and
inflammation.
Eur J
Pharmacol.
2002 Jan
18;435(1):43-
57.

Background

ReN 1869 hydrochloride is a novel, selective histamine H1 receptor antagonist, which demonstrates affinity to the histamine H1 receptor (guinea pig brain) with K_i of $0.19 \pm 0.04 \mu\text{M}$ and the non-selective σ site (guinea pig brain) with K_i of $0.45 \mu\text{M}$.

ReN 1869 is a highly selective tricyclic antihistamine that shows functional histamine H1 receptor antagonism. Binding studies with radioactively labelled ReN 1869 reveals high affinity only for the histamine H1 receptor in addition to some affinity for a sigma site. ReN 1869 is profiled for activity at $10 \mu\text{M}$ at various receptors, transporters, enzymes and ion channels. ReN 1869 only demonstrates affinity to the histamine H1 receptor (guinea pig brain, [^3H]pyrilamine) with a K_i of $0.19 \pm 0.04 \mu\text{M}$ and the non-selective σ site [guinea pig brain, [^3H]1,3-di-tolylguanidine (DTG)] with a K_i of $0.45 \mu\text{M}$. ReN 1869 dose-dependently reduces the responses with IC_{50} of $1.70 \pm 0.002 \mu\text{M}$ [1].

The in vivo binding of [^3H]Mepyramine to mouse spinal cord and cerebellar histamine H1 receptors is dose-dependently inhibited by ReN 1869. ReN 1869 (in doses as low as 10

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

$\mu\text{g}/\text{kg}$ i.p.) significantly inhibits the histamine-evoked paw edema. The ED50 is approximately 300 $\mu\text{g}/\text{kg}$. Interestingly, even a high dose of Mepyramine (10 mg/kg) is unable to inhibit significantly this type of edema (0.29 ± 0.06 versus 0.34 ± 0.05 in controls, $n=7$). ReN 1869 (1 mg/kg s.c.) is administered 30 min before paw injection with carrageenan and has no effect on the development of the paw edema. Dexamethasone (1 mg/kg s.c.) is given 1 h before carrageenan and expectedly diminished the edema. This effect is not affected by the simultaneous administration of 1 mg/kg ReN 1869[1].

[1]. Olsen UB, et al. ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol. 2002 Jan 18;435(1):43-57.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA